Lenacapavir, an antiretroviral drug typically used to treat HIV infections, can also effectively prevent them, a phase 3 ...

In a population of cisgender men, transgender women, transgender men, and gender-nonbinary persons, the incidence of H ...

Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse Persons,” published in the November 2024 issue of Infectious ...

A new HIV prevention method, Lenacapavir, administered as a twice-yearly injection, has demonstrated superior results ...

Scientists have developed Lenacapavir, a twice-yearly injection that cuts HIV infection risk by 96% in groundbreaking trials.

Drugmaker Gilead said it will allow cheap, generic versions to be sold in 120 poor countries with high HIV rates, mostly in ...

Lenacapavir, a new twice-yearly injection, offers 96% HIV prevention efficacy, surpassing daily oral PrEP. For oral ...

Health experts say lenacapavir could reduce the number of global HIV infections significantly. But it needs to be cheaper to ...

A new HIV prevention drug, lenacapavir, has shown 100% effectiveness in women and near-perfect results in men during trials.

"PrEP reduces the risk of getting HIV from sex by about 99 percent when taken as prescribed. Although there is less ...

In 3-year data from the CAPELLA study, the subcutaneous, long-acting capsid inhibitor lenacapavir (Sunlenca) demonstrated ...

We still have 1.3 million new infections a year, the majority of which occur in marginalised and vulnerable groups. But we ...